The answer is hiding in your DNA. For some, it hasn’t been found yet. This CMTA-funded study uses long-read sequencing to uncover genetic causes of CMT that standard tests may miss.
Building the Largest CMT Patient Data Set
CMTA has committed $206,000 over three years to support the Inherited Neuropathy Consortium (INC) in advancing CMT research. Since September 2022, this funding has sustained 20 clinical sites, supported over 20 scientific publications, and enabled large-scale natural history studies of CMT1B and CMT1X. With more than 7,000 patients enrolled, INC’s data set is critical for future clinical trials and Investigational New Drug (IND) approvals.
Solve-CMT Resource: Addressing the Diagnostic Gap and Drug Target Discovery via Advanced Genomics
What happens when CMTA-supported scientists use AI to analyze thousands of CMT genomes for undiscovered genes?
CMTA’s Commitment to The Inherited Neuropathy Consortium
CMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic...
